Dexcom Launches "Dexcom Flex" CGM in Germany as CGM Makers Pivot to Target GLP-1 Users

On May 18, 2026, DexCom, Inc. (Nasdaq: DXCM) announced the launch of Dexcom Flex, a new continuous glucose monitoring (CGM) system designed specifically for adults with Type 2 diabetes who do not use intensive insulin therapy. Initially rolling out in Germany, this new hardware and software system explicitly targets patients using basal insulin, oral therapies, or GLP-1 receptor agonists, representing a major strategic shift by CGM manufacturers to capture the massive and rapidly growing GLP-1 user base.

Redefining CGMs as GLP-1 Companions

Historically, CGMs were marketed almost exclusively to Type 1 and Type 2 diabetes patients on intensive, multi-daily insulin regimens to manage dosing and prevent hypoglycemia. The surge in GLP-1 adoption initially triggered investor anxiety that improved glycemic control from GLP-1s would render CGMs obsolete for non-insulin patients.

Dexcom Flex is a direct commercial response to this threat, reframing the CGM as a companion tool for lifestyle, behavioral, and pharmacological management:

"Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population."

Key features of the Dexcom Flex system include:

• Behavioral and Food Tracking: Real-time glucose monitoring paired with food and activity logging to show patients how diet, exercise, and GLP-1/oral medications interact to impact glucose patterns.
• Personalized Insights: Customized behavioral prompts to help users build long-term habits and understand the metabolic impact of their treatment.
• Hypoglycemia Prevention: Customizable low-glucose alerts to protect patients on basal insulin or combination therapies from dangerous drops.

Expanding the Addressable Market (TAM)

By targeting patients earlier in their Type 2 diabetes journey, Dexcom is aiming to dramatically expand its total addressable market beyond the relatively small pool of intensive-insulin users:

"By supporting people earlier in their Type 2 journey, before they require intensive insulin therapy, Flex may help improve long‑term health outcomes and contribute to meaningful reductions in diabetes-related complications."

Germany was selected as the launchpad due to its progressive digital health reimbursement framework, which subsidizes digital health tools. This launch follows Dexcom's U.S. rollout of Stelo (its over-the-counter CGM) and Abbott's competitive launch of Lingo and Rio, confirming that the CGM industry's primary growth engine has shifted from intensive insulin management to broad metabolic health and GLP-1 integration.